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Abstract
Background: Trachoma, a chronic keratoconjunctivitis caused by Chlamydia trachomatis, is the
world's commonest infectious cause of blindness. Blindness is due to progressive scarring of the
conjunctiva (trachomatous scarring) leading to in-turning of eyelashes (trichiasis) and corneal
opacification. We evaluated the contribution of genetic variation across the chemokine and
cytokine clusters in chromosomes 4q and 5q31 respectively to risk of scarring trachoma and
trichiasis in a large case-control association study in a Gambian population.
Methods: Linkage disequilibrium (LD) mapping was used to investigate risk effects across the 4q
and 5q31 cytokine clusters in relation to the risk of scarring sequelae of ocular Ct infection. Disease
association and epistatic effects were assessed in a population based study of 651 case-control pairs
by conditional logistic regression (CLR) analyses.
Results: LD mapping suggested that genetic effects on risk within these regions mapped to the
pro-inflammatory innate immune genes interleukin 8 (IL8) and granulocyte-macrophage colony
stimulatory factor (CSF2) loci. The IL8-251 rare allele (IL8-251 TT) was associated with protection
from scarring trachoma (OR = 0.29 p = 0.027). The intronic CSF2_27348 A allele in chromosome
5q31 was associated with dose dependent protection from trichiasis, with each copy of the allele
reducing risk by 37% (p = 0.005). There was evidence of epistasis, with effects at IL8 and CSF2 loci
interacting with those previously reported at the MMP9 locus, a gene acting downstream to IL8
and CSF2 in the inflammatory cascade.
Conclusion: innate immune response SNP-haplotypes are linked to ocular Ct sequelae. This work
illustrates the first example of epistatic effects of two genes on trachoma.
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Background
Trachoma is the leading infectious cause of blindness.
Eighty-five million children have active (inflammatory)
trachoma, and about 7 million people, mainly adults, are
blind from late scarring sequelae [1]. For demographic
reasons, the number of people blind due to trachoma may
be increasing [2]. In trachoma, ocular Chlamydia trachom-
atis (Ct) infection causes inflammatory changes in the
conjunctiva, and repeated infections sometimes lead to
fibrosis and scarring of the sub tarsal conjunctiva. This
may cause the upper eyelid margin to turn inwards so that
the lashes rub against the eyeball (trichiasis), which dam-
ages the cornea and leads ultimately to blindness [3].
In trachoma endemic areas most individuals suffer from
ocular Ct infection in childhood. The majority resolve the
infection without permanent sequelae. However, some
individuals develop severe and persistent clinical disease
in response to infection [4,5], and are more likely to
develop conjunctival scarring and trichiasis in later life
[6]. The reasons for this heterogeneity in susceptibility to
chlamydial infection and disease progression following a
rather uniform bacterial exposure remain incompletely
understood; however the host genetic background may
account for part of the risk. Some susceptibility loci have
been mapped to cytokine genes [7-13], but most of the
heritable risk effects in scarring trachoma and trichiasis
are uncharacterised. Identification of genetic loci which
contribute to the burden of trachoma sequelae in the pop-
ulation may help to dissect the immunopathology of ocu-
lar Ct infection in humans.
It has been postulated that the early secretion of pro-
inflammatory cytokines and chemokines by epithelial
cells following Ct  infection may initiate and sustain a
chronic inflammatory process associated with pathology
[14-16]. The chromosomal regions 4q and 5q31, which
are rich in chemokine and cytokine loci respectively, have
been implicated in susceptibility to several common dis-
eases [17-19]. They contain the genes interleukin 8 (IL8)
and granulocyte-macrophage colony stimulatory factor
(CSF2) which have strong candidacy to affect risk of the
scarring complications of trachoma. However, studies of
diversity in these chromosomal segments in the Gambian
population revealed complex genetic features, including
low haplotypic diversity of IL8 [20,21] and a long-range
linkage disequilibrium (LD) pattern spanning CSF2 [22],
both of which extend for several hundred kilobases.
Therefore, observed disease association at the IL8 and
CSF2 loci may potentially map to one or more of the
neighbouring genes. We report here an analysis of the risk
effects at IL8 and CSF2, in a Gambian case-control associ-
ation study of scarring trachoma and trichiasis, which
took the LD structure at these loci into account.
Methods
Study population
651 subjects with scarring trachoma, identified by clinical
examination using WHO criteria and unrelated controls
with normal eyelids pair-matched by age, sex, ethnicity
and village of residence, were recruited for the study.
These were genotyped in two phases; in the first phase,
373 case-control pairs were typed using the full marker
sets. 269 of the cases had trichiasis in addition to scarring.
Mean age was 39 years (range 5-90), and 273 pairs were
female (73%). 32% were of Mandinka ethnicity, 30%
Wolof and 25% Jola. In the second phase, 278 new case-
control samples were further typed with the reduced
marker set, 38 cases had trichiasis in addition to scarring.
Mean age was 34 years, and 193 pairs were female (68%).
5% were Mandinka, 56% Wollof, 24% Fula and 9% Jola.
The sample populations of the two case-control phase
studies (phase 1+ phase 2) differed slightly in age group
and ethnic composition. In the pooled dataset, 651 Gam-
bian subjects with scarring trachoma (307 of them also
had trichiasis), and pair-matched controls with normal
eyelids, 268 individuals were Mandinka (25.8%), 542
were Wolof (33.3%), 236 were Jola (22.6%), 164 were
Fula(10.8%) and 90 (7.5%) were of other ethnic origin.
69% of the recruited subjects were female and the mean
age of the population under study was 37 years.
Subjects gave written consent. The study and its proce-
dures were approved by the Gambia Government/MRC
Ethics Committee (SCC 729/857), the Ethics committees
of the London School of Hygiene and Tropical Medicine
and of Oxford University, and are in accordance with the
Declaration of Helsinki. Subjects diagnosed with trichiasis
were offered free corrective surgery.
DNA extraction and SNP genotyping
Genomic DNA (gDNA) was isolated from either venous
blood in EDTA or buccal brush samples. Genotypes were
determined by the Sequenom system using matrix assisted
laser desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry as previously described [23]. Primer
sequences are available on request.
SNP selection
Initially 9 haplotype tagging SNPs (htSNPs) spanning a
region 330 kb long across the IL8 locus in the Gambian
population [21] (Table 1) and 16 informative htSNP
markers capturing the haplotype block structure within a
656 kb segment of the 5q31 region in Gambians [22]
(Table 2) were genotyped on a subset of 373 case-control
pairs. From these marker sets, two reduced sets of 4
htSNPs covering the IL8 and CSF2 loci respectively were
typed on the remaining 278 case-control pairs.BMC Medical Genetics 2009, 10:138 http://www.biomedcentral.com/1471-2350/10/138
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Analytical methods
Allele and genotype frequencies
Estimates of allele and genotype frequencies were deter-
mined by dividing the total number of each observed
allele (or genotype) by the total number of chromosomes
in the population sample. Genotype distributions at all
loci were in Hardy-Weinberg equilibrium (HWE) in both
cases and controls.
LD estimates
The program HaploXT http://www.sph.umich.edu/csg/
abecasis/gold/docs/haploxt.html was used to calculate
pair-wise LD estimates for the markers, expressed as the
abs D' and R2 parameters (the latter being independent of
the allele frequencies in the population). The input file for
HaploXT was the haplotypes for each control subject gen-
erated by PHASE v2 [24]. The HaploXT output file was
used as an input for MARKER v1.0, a graphical output pro-
gram written by D. Kwiatkowski at the Wellcome Trust
Centre for Human Genetics (WTCHG, Oxford) http://
gmap.net/. These estimates were used to construct haplo-
type blocks of high LD (and reduced within block diver-
sity) within the regions studied.
Table 1: Haplotype tagging SNPs on chromosome 4q genotyped in 373 Gambian case-control pairs
SNP position in 
haplotype
SNP ida Chromosome 
position
Database id SNP genomic 
location
COMMON allele 
(minor allele)
Allele frequency
1 AFP+8865 74300068 rs2298839 intron/exon A(g) 0.41
2 AFM+1666 74338382 rs1894292 intron A(g) 0.24
3 AFM+4530 74341246 rs1894293 intron G(a) 0.33
4 AFM+15790 74352506 rs1158101 intron/exon C(t) 0.14
5 IL8-251 74595248 rs4073 promoter A(T) 0.14
6 IL8+396 74595893 rs2227307 intron T(g) 0.47
7 IL8+37674 74633165 rs13109146 flanking C(t) 0.04
8 IL8+39739 74635230 rs39739 flanking G(a) 0.04
9 IL8+40050 74635538 rs2224434 flanking C(a) 0.14
a SNPs given in bold were selected for typing in the complete sample set of 651 case-control pairs.
Table 2: AFM/IL8 haplotype frequency estimates in cases and controls and risk estimates from CLR analysis of matched case-control 
pairs.
Haplotype a # 
controls
freq # 
cases(TS)
freq p-value CLR:OR 
(95%CI)
# controls freq # 
cases(TT)
freq p-value CLR:OR 
(95%CI)
AGGTAGTAC 215 0.35 195 0.34 - reference 162 0.35 152 0.36 - reference
GAATATTAC 79 0.13 108 0.19 0.061 1.42 
(0.98, 2.04)
55 0.12 75 0.18 0.150 1.38 
(0.89, 2.13)
AGGTATTAC 64 0.10 38 0.07 0.037 0.59 
(0.36, 0.97)
49 0.11 32 0.08 0.113 0.62 
(0.35, 1.12)
GAATAGTAC 50 0.08 51 0.09 0.453 1.20 
(0.75, 1.90)
38 0.08 35 0.08 0.553 1.19 
(0.68, 2.08)
GGGTAGTAC 50 0.08 42 0.07 0.829 0.94 
(0.57, 1.58)
33 0.07 28 0.07 0.489 0.79 
(0.41, 1.53)
GGATATTAC 39 0.06 23 0.04 0.127 0.62 
(0.34, 1.15)
26 0.06 20 0.05 0.420 0.75 
(0.38, 1.50)
AGGTTTTAA 33 0.05 23 0.04 0.323 0.74 
(0.40, 1.35)
28 0.06 16 0.04 0.067 0.50 
(0.24, 1.05)
AGGCAGTAC 23 0.04 26 0.05 0.597 1.18 
(0.63, 2.22)
19 0.04 20 0.05 0.984 1.01 
(0.49, 2.06)
GGACAGTAC 26 0.04 17 0.03 0.356 0.73 
(0.38, 1.42)
20 0.04 13 0.03 0.469 0.75 
(0.35, 1.62)
AGGCATTAC 26 0.04 30 0.05 0.229 1.48 
(0.78, 2.80)
17 0.04 22 0.05 0.286 1.50 
(0.71, 3.15)
GAATTTTAA 14 0.02 18 0.03 0.413 1.39 
(0.63, 3.03)
12 0.03 10 0.02 0.892 0.93 
(0.35, 2.49)
others 145 0.23 157 0.27 - - 97 0.21 115 0.27 - -
a Haplotype configuration: AFP+8865, AFM+1666, AFM+4530, AFM+15790, IL8-251, IL8+396, IL8+37674, IL8+39739, IL8+40050. Others refers to 
population haplotypes of <10% frequency.BMC Medical Genetics 2009, 10:138 http://www.biomedcentral.com/1471-2350/10/138
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Haplotype construction
The program PHASE v2 was used to infer haplotypes from
population genotype data [25] and to estimate the fre-
quency of each inferred haplotype for cases and controls.
To check the accuracy of haplotype reconstruction PHASE
inferred haplotypes were compared with those from the
SNPHAP program for haplotype construction from popu-
lation data http://www-gene.cimr.cam.ac.uk/clayton/soft
ware/snphap.txt.
Association analysis
An adjusted univariate analysis was first carried out by
using Mantel-Haenszel (M-H) chi-square statistics (or
Fisher's exact test if appropriate) to test for differences in
minor allele, genotype and haplotype frequencies
between cases of trachomatous scarring (TS) and of trich-
iasis (TT) with their pair-matched unrelated controls. Sub-
sequently conditional logistic regression (CLR) analysis
for disease association, taking into account matching of
case-control pairs, was performed. In the presentation of
results, reference genotypes were generally selected to be
those that were present at the highest frequency in our
study population. Genotypes conferring susceptibility or
protection are accordingly represented by odds ratios
(OR) of greater than or less than one respectively. A test
for trend in the odds ratios was carried out to check for a
dose response effect relationship between genotype/hap-
lotype and disease allowing for potential confounders. All
analysis was performed using STATA (v8.0) software.
Risk localisation analysis
To localise observed risk effects within the inferred popu-
lation risk haplotype, PHASE assignments from a total of
764 population chromosomes from unrelated Gambian
individuals were made for differing DNA segments by
progressively reducing the number of nearby SNPs used to
infer the population haplotypes. Association analyses
were repeated each time until the risk effects (as measured
by ORs) associated with each DNA segment delimited by
those SNPs started to decrease.
Epistasis
The simplest system of two interacting loci using condi-
tional logistic regression was used to assess epistasis
between MMP9Q279R genotypes, which we previously
reported as conferring risk to scarring trachoma and trich-
iasis, and genotypes at the unlinked IL8 and CSF2 loci.
Because the combination analysis leads to small cell sizes,
we also tested for allelic epistasis, whereby joint risk
effects of two alleles were tested for deviation from addi-
tivity. To assess evidence of epistasis between alleles at
two loci (SNP1 and SNP2) a likelihood ratio test (LRT)
comparing nested models with and without the interac-
tion was performed. The LRT is based on the likelihood
ratio statistic (LRS) with a χ2 distribution with 1 degree of
freedom: LRS = 2(L1-L0) where L1 is the maximum log
likelihood including an interaction term between SNP1
and SNP2 and L0 is the log likelihood under the null
hypothesis of no effect modification of SNP2 on the risk
effects of SNP1, L0 = α+β1 (SNP1)+β2 (SNP2). Genotypic
interactions were analysed similarly but allowing for the
different types of main effect for each genotype (table 1)
Values of p = 0.05 were considered statistically significant.
P-values have not been adjusted for multiple testing. Anal-
ysis was performed using the STATA v8 package.
Results
1 (i) Estimation of risk effects across a 330-kb region of 
chromosome 4q
DNA from 373 Gambian case-control pairs was geno-
typed at 9 SNP sites across 330 kb in chromosome 4q
(table 1, Figure 1). Full-length population haplotypes
inferred using PHASE v2 and population haplotype fre-
quencies determined among cases and controls are shown
in table 2. Pair-wise comparisons of R2 between the 9
typed markers are similar to those identified in the Yoruba
(Figure 1) and Caucasian populations [20,21] with two
broad clusters of association of high-to-moderate pair-
wise LD (R2 > 0.1); cluster 1 including AFP and AFM genes
and cluster 2 including IL8 and its downstream flanking
region (data not shown).
Three out of 11 inferred haplotypes were present at popu-
lation frequency ≥10% and accounted for 60% of all the
haplotypes present in the population (table 2), suggesting
a low haplotype diversity in this genomic region in Gam-
bians. The haplotype AFP+8865G/AFM+1666A,/
AFM+4530A/AFM+15790T/IL8-251A/IL8+396T/
IL8+37674T/IL8+39739A/IL8+40050C, or GAATATTAC,
was associated with increased risk of scarring trachoma, at
borderline of statistical significance, and the haplotype
AGGTATTAC was associated with significant protection
from disease (table 2). In CLR analysis the risk of scarring
increased with copy number of the GAATATTAC haplo-
type and it decreased with increasing copy number of the
AGGTATTAC haplotype (table 3). The risk effects detected
by the high risk haplotype were not affected by those
observed for the low risk haplotype (and vice versa) (data
not shown), suggesting that at least two independent risk
effects may operate in the region.
Pair-wise measures of linkage disequilibrium and regres-
sion modelling (figure 1, table 3) mapped the risk associ-
ations to the four contiguous SNPs bounded by
AFM+1666 and IL8-251 (AFM+1666A/AFM+4530A/
AFM+15790T/IL8-251A OR(95%CI) = 2.00 (1.30, 2,94)
and 1.610 (0.99, 2.61) for scarring and trichiasis respec-
tively). CLR analyses suggested that the AFM+1666 and
AFM+4530 SNP sites explain mainly the high risk effects
detected by the risk AATA (H2) haplotype whereas IL8-BMC Medical Genetics 2009, 10:138 http://www.biomedcentral.com/1471-2350/10/138
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Top: Hapmap data of LD spanning a 330 kb segment of chromosome 4q in the Yoruba (Nigerian) population (LD map drawn  using MARKER (see methods)) Figure 1
Top: Hapmap data of LD spanning a 330 kb segment of chromosome 4q in the Yoruba (Nigerian) population 
(LD map drawn using MARKER (see methods)); LD between each SNP pair is colour-coded (red dots represent an 
absolute R2 > 0.3, green dots indicate R2 of 0.1 to 0.3, grey dots indicate R2 of 0.05 to 0.1 and absence of dots represents pairs 
with R2 ≤ 0.05). Middle: Genes on the segment are indicated as black boxes, the position of the 9 SNP markers as vertical lines 
below the boxes, with arrows indicating direction of transcription. Bottom: Haplotype structure of the genomic segment in 
Gambians illustrating four haplotype blocks of high within- and low between-cluster diversity and the haplotype frequencies 
within each block beneath. Dots and shading indicate the configuration of the protective and risk haplotypes respectively. The 
dark shading spanning the IL8 locus shows the configuration in blocks 3 and 4 which is shared by the risk and protective haplo-
types, differing only at SNP positions 1, 2 and 3 across the AFP and AFM loci but sharing allelic configuration at sites within, and 
telomeric to, IL8.BMC Medical Genetics 2009, 10:138 http://www.biomedcentral.com/1471-2350/10/138
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251 SNP tags some of the risk effects captured by the
GGTA (L2) haplotype (data not shown).
When the risk haplotype tagging SNPs AFM+1666,
AFM+4530, AFM+15790 and IL8-251 were retested for
disease association in the complete case-control sample
set of 651 case-control pairs, the AATA haplotype, present
in 23% of the population, was found to be associated with
an increased risk of trichiasis (OR = 1.39, 95%CI = 1.03,
1.88) with risk effects increasing 40% for each copy of the
haplotype (OR = 1.40, 95%CI = 1.04, 1.87). On the other
hand the rare IL8-251TT genotype (2.4% population fre-
quency) was associated with reduced risk of scarring tra-
choma (OR for scarring 0.29, 95% CI = 0.09, 0.87, p =
0.027 and for trichiasis 0.50, 95%CI = 0.04, 5.51, p =
0.571 for IL8-251 TT versus IL8-251 AA+AT). The relative
risk of developing scarring among IL8-251 TT homozy-
gotes was estimated to be 2 times lower in the younger
group (<35 years old) than in the older group (≥ 35 years),
although this difference in risks was not statistically signif-
icant possibly due to small sample sizes (data not shown).
The risk effects of the AATA haplotype were independent
of the IL8-251 TT protective effects suggesting that the risk
tagged by the haplotype may be independent of that
detected by the IL8-251 TT genotype (data not shown).
1 (ii) Epistasis between IL8-251 and MMP9 Q279R SNPs
There was some evidence for interaction between the
MMP9 Q279R and IL8-251 alleles affecting risk of scar-
ring trachoma (LRT χ2 = 4.14, p = 0.042). The protective
effect of the IL8 T allele was significantly increased, by
more than 70%, in subjects carrying the MMP9 G protec-
tive allele (OR, 95%CI = 0.352 (0.14, 0.87) but sup-
pressed in the presence of the MMP9 Q279R A risk allele
(OR, (95%CI) = 1.90, (0.67, 1.21). No significant interac-
tion effects were noted at the genotype level, although the
number of IL8-251TT homozygotes is small. There was no
evidence for gene-gene interaction involving MMP9
Q279R and either AFM+1666 or AFM+4500 (data not
shown).
2(i) Estimation of risk effects across a 656 kb region of 
chromosome 5q
In brief, due to the irregular LD between the IL3/CSF2 and
IL13/IL4 regions (Figure 2), genotyping data were used to
construct 8 marker haplotypes across each of these two
regions in 746 unrelated chromosome pairs (Table 4). LD
statistics obtained from the haplotype data were in agree-
ment with published data [22]. A significant association
was observed between two 8 SNP-haplotypes delimiting a
genomic block of high LD across IL3 and CSF2, and risk
of scarring (Figure 2; tables 5 and 6). No significant risk
effects were detected across the IL13 and IL4 loci (data not
shown).
Following a similar approach to that of the IL8 region,
PHASE assignments on progressively reducing SNP sets
fine-mapped SNP-haplotype risk effects to 3 contiguous
haplotype tagging SNPs bounded by CSF2_27348 and
CSF2_27438 spanning the IL3 and CSF2 loci, (figure 2,
tables 5 and 6). The high and low risk extended haplo-
types shared the SNP alleles in IL3 (tables 5 and 6).
The CSF2_27348A/CSF2_2069614T/CSF2_27438A hap-
lotype (ATA), of 17% population frequency, was found to
be associated with lower risk of scarring and trichiasis
(OR, (95%CI) of 0.82, (0.65, 1.04) and 0.61, (0.42, 1.88)
for scarring trachoma and trichiasis respectively), decreas-
ing with copy number (OR, 95%CI for test for trend of
0.82(0.66, 1.01) and OR of 0.65 (0.47, 0.89) for scarring
trachoma and trichiasis respectively). Among common
population haplotypes, ATA is unique in that it exclu-
sively carries the CSF2_27348 A low risk allele. The risk
effects detected by haplotype and single-marker analyses
are very close (tables 5, 6, 7 &8) adding evidence to the
idea that ATA haplotype and the CSF2_27348 A allele may
capture the same risk effects within the region. This was
further confirmed by logistic regression analyses showing
that the haplotype risk effects are not significant when
adjusted for the risk effects of CSF2_27348 (and vice versa)
(data not shown). The risk associated with the
CSF2_27438 SNP is best described by a recessive model
Table 3: risk effects estimated by OR (95%CI) for the association between extended (H1, L1) and reduced (H2, L2) haplotypes with 
scarring trachoma and trichiasis.
HAPa SNP b CLR test for trend
Scarring trachoma Trichiasis
123456 7 8 9 OR 95%CI p value OR 95%CI p value
H1 G A A T A T T A C 1.671 1.19,2.35 0.003 1.616 1.08, 2.42 0.020
H2 - AA-A- - - - 1.541 1.14,2.08 0.005 1.510 1.05, 2.15 0.025
L1 A G G T A T T A C 0.556 0.36,0.87 0.010 0.685 0.40, 1.16 0.161
L2 - GG-A- - - - 0.490 0.27,0.89 0.021 0.725 0.378,1.39 0.334
a Significant associations are fine-mapped to four contiguous ht SNPs bounded by AFM+1666 and IL8-251 (H2 and L2 haplotypes). Regression 
modelling with PHASE inferred haplotypes from progressively reducing SNP sets showed increased risk effects of similar magnitude in the reduced 
set compared to those detected by the full length haplotypes.
b Refer to table 1 for SNP informationBMC Medical Genetics 2009, 10:138 http://www.biomedcentral.com/1471-2350/10/138
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(GG vs AG + AA genotypes). A protective effect at
CSF2_27348 was also most marked in a recessive model
for the minor genotype AA vs TT+AT. There was some evi-
dence for a dose-response effect towards decreasing risk of
disease with increasing number of copies of the
CSF2_27348 A minor allele (tables 7 and 8).
2 (ii) Epistatic effects between CSF2_27348 and MMP9 
Q279R SNPs
Evidence for interaction was observed between genotypes
at the MMP9 Q279R and CSF2_27348 loci (CSF2_27348
- MMP9 Q279R recessive-heterozygote advantage disease
model (LTR χ2 = 8.08 p = 0.005)). MMP9 Q279R AG het-
erozygotes were most protected from risk of trichiasis
when this genotype was combined with the CSF2_27348
TT genotype (OR, (95%CI) = 0.41 (0.25, 0.66). In contrast
MMP9 Q279AG/CSF2_27348 AA conferred increased risk
of trichiasis (OR, (95%CI) = 7.55 (1.01, 56.71) with wide
confidence intervals resulting from the small number of
subjects with the CSF2_27348 AA genotype.
Discussion
By means of combining LD mapping, case-control and
epistatic analyses we have identified a genetic association
between severe outcome of ocular Ct infection and the
pro-inflammatory genes IL8 and CSF2 within the chem-
okine and cytokine gene clusters in chromosomes 4q and
5q31 respectively. These two pro-inflammatory mediators
characterise an early host response to Ct infection thought
to act to augment the innate immunity essential for host
defence or, if unchecked, cause cytotoxic damage to the
epithelium [14,15,26].
Homozygotes for the IL8-251T promoter region allele
showed a greatly reduced risk of scarring trachoma. How-
ever the prevalence of the IL8-251TT genotype was low
(2.4%) in our population indicating that a larger case-
control series will be needed to get accurate estimates of
risk effects. The degree of protection was greater in
younger compared to older age groups suggesting that
effects linked to IL8-251 may be particularly relevant to
the development of scarring trachoma and trichiasis at an
Table 4: list of haplotype tagging SNPs on chromosome 5q genotyped in 373 case-control pairs. 
SNP position in 
haplotype A or B
SNP ida Chromosome 
position
Database id SNP genomic 
location
COMMON allele 
(minor allele)
Allele frequency
1A IL3_2069783 131471923 rs2069783 5'UTR T(c) 0.18
2A IL3_31480 131472548 rs31480 5'UTR G(a) 0.05
3A IL3_40401 131472694 rs40401 exon C(t) 0.45
4A IL3_31481 131473418 rs31481 intron G(a) 0.14
5A CSF2_27348 131483355 rs27348 3'UTR T(a) 0.39
6A CSF2_2069614 131483817 rs2069614 3'UTR T(c) 0.45
7A CSF2_27438 131489471 rs27438 3'UTR A(g) 0.23
8A CSF2_2069632 131489516 rs2069632 3'UTR C(t) 0.27
1B IL13_46457 132072180 rs20541 exon C(t) 0.14
2B IL13_46578 132072059 rs1295686 splice site A(g) 0.27
3B IL13_49612 132069025 rs1800925 5'UTR G(a) 0.40
4B IL4-589 132085370 rs2243250 5'UTR T(c) 0.27
5B IL4+33 132085926 rs2070874 exon C(t) 0.49
6B IL4_2243251 132086003 rs2243251 5'UTR T(c) 0.19
7B IL4_2227284 132088941 rs2227284 intron A(c) 0.05
8B IL4_2243270 132090325 rs2243270 intron C(t) 0.27
SNPs given in bold were selected for typing in the complete sample set of 651 case-control pairs
aSNPs given in bold were selected for typing in the complete sample set of 651 case-control pairs.
Table 5: Risk effects estimated by OR (95%CI) for the association between extended and reduced haplotypes across IL3 and CSF2 and 
risk of scarring trachoma and trichiasis.
HAP SNPa CLR
Scarring trachoma Trichiasis
1A 2A 3A 4A 5A 6A 7A 8A OR 95%CI p value OR 95%CI p value
H1 T C C G T C G C 1.370 1.070,1.763 0.010 1.390 1.040,1.869 0.030
H2 ---- TCG- 1.032 0.830,1.280 0.778 1.131 0.822,1.556 0.448
L1 T C C G A T A C 0.804 0.520,1.220 0.324 0.871 0.520,1.378 0.609
L2 ---- ATA- 0.820 0.650,1.043 0.084 0.610 0.423,0.880 0.008
a Refer to table 4 for SNP informationBMC Medical Genetics 2009, 10:138 http://www.biomedcentral.com/1471-2350/10/138
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Table 6: Test for trend in risk of scarring trachoma or trichiasis with copy number for each haplotype. 
HAP SNPa CLR test for trend
Scarring trachoma Trichiasis
1A 2A 3A 4A 5A 6A 7A 8A OR 95%CI p value OR 95%CI p value
H1 T C C G T C G C 1.300 1.002,1.670 0.048 1.322 0.980,1.790 0.071
H2 ---- TCG- 1.086 0.854,1.380 0.502 1.242 0.935,1.645 0.135
L1 T C C G A T A C 0.839 0.555,1.267 0.403 0.656 0.405,1.060 0.087
L2 ---- ATA- 0.755 0.567,1.005 0.065 0.617 0.438,0.870 0.006
OR >1 indicates an increase in risk with copy number and OR <1 a decrease.
aRefer to table 4 for SNP information
Top: LD map across a 656 kb segment of the 5q31 region in the Gambian population [22] Figure 2
Top: LD map across a 656 kb segment of the 5q31 region in the Gambian population [22]. Middle: Distribution of 
the 16 most informative markers (Table 4) that capture the haplotype block structure extending from IL3 to IL4. Bottom; 
Haplotype structure defined by 8 SNP markers across IL3 and CSF2 illustrating two haplotype blocks and haplotype frequen-
cies within each block beneath. Dots and shading indicate the configuration of the protective and risk haplotypes respectively; 
the dark shading spanning the IL3 locus shows the haplotype configuration shared by the risk and protective haplotypes.BMC Medical Genetics 2009, 10:138 http://www.biomedcentral.com/1471-2350/10/138
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early age. Cases and controls were matched by age and vil-
lage of residence, so that this age difference is not
accounted for by different treatment history (treatment is
programmed per village) or environmental influences.
The IL-251A common allele has been correlated with high
IL8 expression in vitro [27] and also with an increased sus-
ceptibility to respiratory syncytial virus (RSV) bronchioli-
tis [21,27], a chronic inflammatory disease characterised
by high levels of IL8 and neutrophil infiltration of the air-
way epithelium. It is therefore plausible that, in IL8-251T
homozygotes, genetically controlled production of low
IL-8 levels by Ct infected cells in the conjunctival epithe-
lium leads to decreased activation and migration of neu-
trophils to the site of infection. The subsequent reduction
in inflammation and cytotoxic epithelial damage, may
ultimately protect the conjunctiva from the development
of severe trachoma sequelae. The genetic risk effects for
scarring and trichiasis observed in this genomic region are
similar, which suggests that the above molecular mecha-
nism may be common to the development of both phe-
notypes, rather than implicated in the progression of
scarring to trichiasis.
Fine mapping of susceptibility to RSV bronchiolitis at this
locus [21] suggested that additional risk variants in the
region mapped to a region excluding the AFM gene
(which codes for an albumin-like protein expressed in the
liver) but including the novel gene RASSF6, a member of
the Ras superfamily of small GTPases that can mediate
bacterial entry by controlling changes in the actin
cytoskeleton [28-30]. Here we show that the risk effect on
trachoma maps to the region bounded by the AFM+1666
and IL-251 markers which contains RASSF6 (Figure 1).
Interestingly, by means of gene expression microarray
analyses, we have found that the RASSF6 expression pat-
tern maps to a cluster of genes involved in reorganization
of the actin cytoskeleton whose expression is up-regulated
Table 7: Proportions of cases and controls with different SNP-genotypes at the CSF2 locus and risk estimates from conditional logistic 
regression (CLR) analysis of 651 matched case-control pairs for each SNP for scarring trachoma.
Multiplicative model Dominant model Recessive model
Genotype # of genotypes (freq) CLR OR (95%CI) OR (95%CI)
TS cases controls OR (95%CI) P value P value P value
GM-CSF2_27348 TT 391(0.65) 384(0.61) Reference - 0.86(0.67,1.09) 0.60(0.33,0.084)
GM-CSF2_27348 TA 193(0.32) 207(0.33) 0.90(0.70,1.57) 0.414 0.200 0.084
GM-CSF2_27348 AA 22 (0.04) 36 (0.06) 0.58(0.32,1.04) 0.069
Test for trend 0.84(0.69,1.03) 0.091
GM-CSF2_2069614 CC 206(0.32) 198(0.31) Reference - 0.88(0.68,1.28) 0.99 (0.74,1.31)
GM-CSF2_2069614 CT 306(0.48) 316(0.49) 0.87(0.67,1.31) 0.300 0.310 0.922
GM-CSF2_2069614 TT 124(0.19) 130(0.20) 0.90(0.65,1.26) 0.546
Test for trend 0.94(0.80,1.11) 0.467
GM-CSF2_27438 AA 215(0.33) 233(0.36) Reference - 1.08(0.85,1.37) 1.37 (1.02,1.85)
GM-CSF2_27438 AG 301(0.47) 318(0.49) 1.00(0.78,1.29) 0.991 0.542 0.037
GM-CSF2_27438 GG 126(0.20) 100(0.15) 1.37(0.98,1.93) 0.066
Test for trend 1.14(0.97,1.35) 0.113
Table 8: Proportions of cases and controls with different SNP-genotypes at the CSF2 locus and risk estimates from conditional logistic 
regression (CLR) analysis of matched 307 case-control pairs for each SNP for trichiasis
Multiplicative model Dominant model Recessive model
Genotype # of genotypes (freq) CLR OR (95%CI) OR (95%CI)
TT cases controls OR (95%CI) P value P value P value
GM-CSF2_27348 TT 198(0.69) 179(0.59) Reference - 0.62(0.42,0.90) 0.42 (0.18,0.98)
GM-CSF2_27348 TA 82 (0.28) 103(0.34) 0.67(0.45,0.99) 0.048 0.012 0.046
GM-CSF2_27348 AA 9 (0.03) 20 (0.07) 0.37(0.16,0.87) 0.024
Test for trend 0.64(0.47,0.88) 0.005
GM-CSF2_2069614CC 108(0.36) 94 (0.31) Reference - 0.77(0.57,1.12) 0.82 (0.53,1.26)
GM-CSF2_2069614 CT 138(0.46) 146(0.48) 0.79(0.53,1.18) 0.254 0.171 0.359
GM-CSF2_2069614 TT 54 (0.18) 65 (0.21) 0.70(0.42,1.16) 0.172
Test for trend 0.83(0.65,1.07) 0.154
GM-CSF2_27438 AA 101(0.33) 127(0.40) Reference - 1.29(0.91,1.83) 1.14 (0.74,1.75)
GM-CSF2_27438 AG 145(0.48) 132(0.42) 1.28(0.88,1.85) 0.195 0.157 0.56
GM-CSF2_27438 GG 57 (0.19) 55(0.18) 1.31(0.81,2.13) 0.268
Test for trend 1.17(0.92,1.48) 0.203BMC Medical Genetics 2009, 10:138 http://www.biomedcentral.com/1471-2350/10/138
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in the Ct infected conjunctiva of Gambians (unpublished
data).
The functionality of the 2 intronic risk variants detected
here across CSF2 is not obvious from genome annotation
and it is possible that these SNPs act only as markers for a
yet unidentified functional element. The CSF2_27348
marker has been found to be linked to the rs721121 SNP,
located in an enhancer site for the inducible transcription
factor AP1, an intergenic enhancer required for the cor-
rectly regulated activation of both CSF2 and IL3 gene
expression in T cells [31]. Among other genes neighbour-
ing CSF2 that need to be considered as candidates for the
origin of the risk effects is SLC22A4 (Figure 2). This gene
codes for an organic cation transported in lymphoid
organs [32] which has been associated with risk of rheu-
matoid arthritis [32]. We have recently found that the
transcriptional levels of SLC22A4 are increased in the con-
junctiva of subjects with inflammatory trachoma and ocu-
lar Ct infection, mapping to a gene cluster characteristic of
an innate immune response pattern of expression
(unpublished data). Similarly to RASSF6, the role of
SLC22A4 in the inflamed conjunctiva remains to be eluci-
dated.
The statistical interaction (epistasis) observed between the
risk variants within IL8 and CSF2 and the Q279R exonic
SNP in MMP9, a collagenase thought to be involved in the
inflammatory and scarring processes of Ct  infection
[11,33,34], may further suggest how genetic variation
detected in IL8 and CSF2 could affect risk of trachoma:
IL8, CSF2 and MMP9 are co-expressed in the Ct infected
conjunctiva [34], unpublished data). These gene products
could interact at the site of infection to augment and sus-
tain inflammatory processes. MMP9 has been found to
greatly enhance the activity of IL8 by amino-terminal
processing[35], whereas activation of neutrophils by IL-8
may trigger the release of pro-MMP9 [36,37], creating a
potential for a positive feedback loop. Similarly, CSF2
release by Ct infected epithelial cells [15,16] may mediate
the influx and activation of inflammatory cells at the site
of infection. Secreted CSF2 may trigger MMP9 production
by monocytes [38], which could act to enhance and sus-
tain the pro-inflammatory cascade initiated by CSF2. Thus
the epistatic genetic risk effects could reflect biological
interactions between their products, allowing a mecha-
nism by which genetic variation affecting IL8 and CSF2
expression/activity change the risk effects associated with
MMP9 variants and vice versa. Epistasis has not been
reported before in studies of susceptibility to trachoma
but may be an important feature of highly regulated gene
networks.
Conclusion
This study provides the first evidence that genetic suscep-
tibility determinants for severe sequelae of ocular Ct infec-
tion may exist among innate response genes. This work
adds to recent observations [39,40] suggesting that innate
immune responses in early inflammatory events during
acute infection with Ct may have both favourable and det-
rimental effects in the development of irreversible seque-
lae of Ct infection. Although we narrow down the limits
of disease association to a few candidates within these
genomic regions, which are complex and rich in immune
genes, the results should be interpreted with caution.
Functionally important SNPs directly influencing risk of
disease remain to be uncovered; the complex and locus-
specific architecture of the 4q and 5q31 genomic regions
requires 'deeper' genotyping with a higher density of
markers and increased sample sizes.
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